As of 04 Nov 2026 18:36 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from MSN/2023/084 (14 Sep 2023): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Estradiol valerate/medroxyprogesterone acetate (Indivina®) 1mg/5mg tabletsaffected product · inferred from phrasing | Out of stock, as stated | w/c 11th December 2023precision: a month · window end 17 Dec 2023, derived from “w/c 11th December 2023” | notice of 14 Sep 2023 |
| Alternative continuous combined hormone replacement therapies (HRT) containing estradiol 1mg but a different progesterone componentnamed by the source as remaining available · inferred from phrasing | Stated as available | — not stated for this line | notice of 14 Sep 2023 |
| Estradiol valerate/medroxyprogesterone acetate (Indivina®) 1mg/2.5mg tabletsnamed by the source as remaining available · inferred from phrasing | Stated as available; cannot support an uplift in demand | — not stated for this line | notice of 14 Sep 2023 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register — 8 earlier protocols on this record have expired: SSP031 (to 12 May 2023), SSP030 (to 12 May 2023), SSP029 (to 12 May 2023), SSP028 (to 13 Jan 2023), SSP027 (to 13 Jan 2023), SSP026 (to 13 Jan 2023), SSP023 (to 30 Nov 2022), SSP022 (to 30 Nov 2022). Matching is by name until identifier coding lands.
Named in the source as remaining available
- Alternative continuous combined hormone replacement therapies (HRT) containing estradiol 1mg but a different progesterone component — named by the source as remaining available (inferred from phrasing)
- Estradiol valerate/medroxyprogesterone acetate (Indivina®) 1mg/2.5mg tablets — named by the source as remaining available (inferred from phrasing)
Only names the source itself listed, as it listed them (source post ↗). No substitution, dosing or counselling advice is given here or implied.
Identifiers — Estradiol Valerate
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name (chemical name), confidence 0.85 — grouping under review where marked Release Jul 2026.
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
Notified short 2 times on record since 2023. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 14 Sep 2023 | Medicine Supply Notification: Estradiol valerate/medroxyprogesterone acetate (Indivina® ) 1mg/5mg tablets | Supply notification | Tier 2 | MSN/2023/084 |
| 27 Mar 2023 | Medicine Supply Notification: Estradiol valerate/medroxyprogesterone acetate (Indivina® ) 1mg/2.5mg tablets | Supply notification | Tier 2 | MSN/2023/034 |
Also recorded under
Bracketed names seen in this medicine's notice titles: indivina. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
NHS Scotland issues its own Medicine Supply Alert Notices. These match this medicine's name; they are shown beside, never added to, the England record.
- MSAN(2023)24 Estradiol valerate/medroxyprogesterone acetate (Indivina®) 1mg/5mg tablets · issued 19 Sep 2023 · valid until w/c 11th December 2023, as stated · matched by name PDF ↗